Parallel detection of (1→3)-β-D-Glucan in corresponding same day urine and serum samples obtained from patients with hematological malignancies

Abstract

Background: Serum 1,3-beta-D-glucan (BDG) testing is an diagnostic marker for invasive fungal infections (IFI) applied for patients with hematological malignancies. Though for the application of BDG urine testing, currently limited data exists. Methods: Serum and urine samples were collected on the same day, twice a week in parallel, from adult patients with underlying hematological malignancies. A total of 241 urine samples from 60 patients were investigated with the BDG Fungitell® assay. In addition, a BDG/Creatinine ratio to exclude urine dilution bias was introduced. Results: 19 had positive corresponding serum BDG (>200 pg/ml), 33 intermediate (80-200 pg/ml), and 189 negative serum BDG (200 pg/ml (BDG urine: r=0.453; p=0.051; urine BDG/Creatinine ratio: r=0.722; p=0.000) compared to the negative and intermediate ranges. Conclusion: Overall correlation of same-day urine BDG and serum BDG was moderate. In general correlation and the clinical performance was superior when the urine BDG/Creatinine ratio was applied, therefore urine BDG testing in urine could be improved by introducing a BDG/Creatinine ratio.

Date of Award	2016
Original language	English
Awarding Institution	Medical University Graz
Supervisor	Jasmin Rabensteiner (Supervisor)